Abstract
[This corrects the article DOI: 10.3389/fendo.2021.637209.].
Highlights
Marketed in Korea for childhoodGHD; approved in Europe but not (41), safety data from a Korean registry hyaluronate and dispersed in marketed in the EU database in children with growth disorders an oil base of medium-chain (42), Phase 2 trial in children with ISS triglycerides (22 kDa) demonstrated non-inferiority and welltolerated (43)
Reviewed by: Martin Bidlingmaier, Ludwig Maximilian University of Munich, Germany Roberto Salvatori, Johns Hopkins University, United States
Specialty section: This article was submitted to Pituitary Endocrinology, a section of the journal Frontiers in Endocrinology
Summary
GHD; approved in Europe but not (41), safety data from a Korean registry hyaluronate and dispersed in marketed in the EU database in children with growth disorders an oil base of medium-chain (42), Phase 2 trial in children with ISS triglycerides (22 kDa) demonstrated non-inferiority and welltolerated (43). PEGylation prolongs in vivo mean residence time of GH, through slowing absorption and protection from proteolysis. 30-kDa PEG added to unnatural amino acid incorporated into GH (52 kDa) Site-specific PEGylated GH analog (not available) 40-kDa PEG attached to GH (62 kDa). No longer being developed (39) due to PEGylated-containing vacuoles in the epithelial cells of the choroid plexus in monkeys (44) Preclinical studies (45)
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call